Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 12/2018

Open Access 01-11-2018 | Thoracic Oncology

Prognostic Significance of Albumin–Globulin Score in Patients with Operable Non-Small-Cell Lung Cancer

Authors: Xiang Li, MD, Sida Qin, MD, Xin Sun, MD, Dapeng Liu, MD, Boxiang Zhang, MD, Guodong Xiao, PhD, Hong Ren, MD

Published in: Annals of Surgical Oncology | Issue 12/2018

Login to get access

Abstract

Objective

This study was designed to evaluate the prognostic value of the preoperative albumin–globulin score (AGS) in the patients with non-small cell lung cancer (NSCLC) after pulmonary lobectomy.

Methods and Results

The optimal cutoff level was 40.00 and 27.05 g/L for Alb and Glb, respectively. Based on this and the previous study, patients with both an hypoalbuminemia (< 40.00 g/L) and an elevated Glb level (≥ 27.05 g/L) were assigned a score of 2, and patients with one or neither were assigned a score of 1 or 0, respectively. We investigated the correlations between the AGS and the clinicopathological characteristics of patients and found that AGS was significantly associated with TNM stage (P = 0.016). Multivariate Cox analyses indicated that the AGS was an independent prognostic indicator for NSCLC for disease-free survival (DFS) (P = 0.001) and overall survival (OS) (P = 0.004). Kaplan–Meier analysis and log-rank test demonstrated that there were significant differences in DFS (P < 0.001) and OS (P < 0.001) among the three AGS groups. Furthermore, our study showed that DFS and OS are significantly different in three groups of patients with different AGS, in both Squamous carcinoma (P < 0.001 for DFS; P < 0.001 for OS) or adenocarcinoma (P = 0.034 for DFS; P = 0.035 for OS). In addition, we enrolled 53 patients as an independent set of cases for the further validation of AGS. Multivariate analyses verified AGS was an independent prognostic factor for NSCLC patients (P = 0.020 for DFS; P = 0.018 for OS).

Conclusions

Preoperative AGS is an independent prognostic factor for patients with operable NSCLC.
Literature
1.
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115.CrossRefPubMed
2.
3.
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh T, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123–32.CrossRefPubMed
4.
Iragavarapu C, Mustafa M, Akinleye A, Furqan M, Mittal V, Cang S, Liu D. Novel ALK inhibitors in clinical use and development. J Hematol Oncol. 2015;8(1):17.CrossRefPubMedPubMedCentral
5.
Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9(1):34.CrossRefPubMedPubMedCentral
6.
7.
Bria E, Milella M, Sperduti I, Alessandrini G, Visca P, Corzani F, Giannarelli D, Cerasoli V, Cuppone F, Cecere FL. A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer. Lung Cancer. 2009;66(3):365–71.CrossRefPubMed
8.
Wang CL, Li Y, Yue DS, Zhang LM, Zhang ZF, Sun BS: Value of the metastatic lymph node ratio for predicting the prognosis of non-small-cell lung cancer patients. World J Surg. 2012;36(2):455-62.CrossRefPubMed
9.
Koh YW, Lee HW: Prognostic impact of C-reactive protein/albumin ratio on the overall survival of patients with advanced nonsmall cell lung cancers receiving palliative chemotherapy. Medicine. 2017;96(19):e6848.CrossRefPubMedPubMedCentral
10.
Cedrés S, Torrejon D, Martínez A, Martinez P, Navarro A, Zamora E, Muletmargalef N, Felip E. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol. 2012;14(11):864.CrossRefPubMed
11.
Gu X, Sun S, Gao XS, Xiong W, Qin S, Qi X, Ma M, Li X, Zhou D, Wang W. Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3430 patients. Sci Rep. 2016;6:22618.CrossRef
12.
Zhang H, Xia H, Zhang L, Zhang B, Yue D, Wang C. Clinical significance of preoperative neutrophil–lymphocyte vs platelet–lymphocyte ratio in primary operable patients with non–small cell lung cancer. Am J Surg. 2015;210(3):526–35.CrossRefPubMed
13.
Kim SH, Lee HW, Go SI, Lee SI, Lee GW: Clinical significance of the preoperative platelet count and platelet-to-lymphocyte ratio (PLT-PLR) in patients with surgically resected non-small cell lung cancer. Oncotarget. 2016;7(24):36198.CrossRefPubMedPubMedCentral
14.
Mcmillan DC: Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009;12(3):223.CrossRefPubMed
15.
Al-Shaiba R, Mcmillan DC, Angerson WJ, Leen E, Mcardle CS, Horgan P. The relationship between hypoalbuminaemia, tumour volume and the systemic inflammatory response in patients with colorectal liver metastases. Br J Cancer. 2004;91(2):205–7.CrossRefPubMedPubMedCentral
16.
Barbosa-Silva MC: Subjective and objective nutritional assessment methods: what do they really assess? Curr Opin Clin Nutr Metab Care. 2008;11(3):248–54.CrossRefPubMed
17.
Yildirim M, Yildiz M, Duman E, Goktas S, Kaya V. Prognostic importance of the nutritional status and systemic inflammatory response in non-small cell lung cancer. J Buon. 2013;18(3):728.PubMed
18.
Azab B, Kedia S, Shah N, Vonfrolio S, Lu W, Naboush A, Mohammed F, Bloom SW. The value of the pretreatment albumin/globulin ratio in predicting the long-term survival in colorectal cancer. Int J Colorectal Dis. 2013;28(12):1629–36.CrossRefPubMed
19.
Azab BN, Bhatt VR, Vonfrolio S, Bachir R, Rubinshteyn V, Alkaied H, Habeshy A, Patel J, Picon AI, Bloom SW. Value of the pretreatment albumin to globulin ratio in predicting long-term mortality in breast cancer patients. Am J Surg. 2013;206(5):764–70.CrossRefPubMed
20.
Duran AO, Inanc M, Karaca H, Dogan I, Berk V, Bozkurt O, Ozaslan E, Ucar M, Eroglu C, Ozkan M: Albumin-globulin ratio for prediction of long-term mortality in lung adenocarcinoma patients. Asian Pacific J Cancer Prev Apjcp. 2014;15(15):6449–53.CrossRefPubMed
21.
Liu J, Chen S, Geng Q, Liu X, Kong P, Zhan Y, Xu D. Prognostic value of pretreatment albumin-globulin ratio in predicting long-term mortality in gastric cancer patients who underwent D2 resection. Oncotargets Ther. 2017;10:2155.CrossRef
22.
Bo Z, Wei Y, Zhou LQ, He ZS, Cheng S, He Q, Li J, Liu LB, Cong W, Chen XY. Prognostic significance of preoperative albumin-globulin ratio in patients with upper tract urothelial carcinoma. PLoS One. 2015;10(12):e0144961.CrossRef
23.
Zhang F, Sun P, Wang Z, Wang D, Wang Y, Zhang D, Wang F, Fu J, Xu R, Li Y. Low preoperative albumin-globulin score predicts favorable survival in esophageal squamous cell carcinoma. Oncotarget. 2016;7(21):30550–60.PubMedCentralPubMed
24.
Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K, Fushiya N, Koike K, Nishino H, Matsushima M. The C-reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma. Ann Surg Oncol. 2015;22(3):803–10.CrossRefPubMed
25.
Zhou T, Zhan J, Hong S, Hu Z, Fang W, Qin T, Ma Y, Yang Y, He X, Zhao Y. Ratio of C-reactive protein/albumin is an inflammatory prognostic score for predicting overall survival of patients with small-cell lung cancer. Sci Rep. 2015;5:10481.CrossRefPubMedPubMedCentral
26.
Xu XL, Yu HQ, Hu W, Song Q, Mao WM. A novel inflammation-based prognostic score, the c-reactive protein/albumin ratio predicts the prognosis of patients with operable esophageal squamous cell carcinoma. PLoS One. 2015;10(9):e0138657.CrossRefPubMedPubMedCentral
27.
Shibutani M, Maeda K, Nagahara H, Ohtani H, Iseki Y, Ikeya T, Sugano K, Hirakawa K. The pretreatment albumin to globulin ratio predicts chemotherapeutic outcomes in patients with unresectable metastatic colorectal cancer. BMC Cancer. 2015;15(1):347.CrossRefPubMedPubMedCentral
28.
Mcmillan DC, Watson WS, O’Gorman P, Preston T, Scott HR, Mcardle CS. Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer. 2001;39(2):210.CrossRefPubMed
29.
Oñate-Ocaña LF, Aiello-Crocifoglio V, Gallardo-Rincón D, Herrera-Goepfert R, Brom-Valladares R, Carrillo JF, Cervera E, Mohar-Betancourt A. Serum albumin as a significant prognostic factor for patients with gastric carcinoma. Ann Surg Oncol. 2007;14(2):381–9.CrossRefPubMed
30.
Chojkier M. Inhibition of albumin synthesis in chronic diseases: molecular mechanisms. J Clin Gastroenterol. 2005;39(2):143–6.CrossRef
31.
Boonpipattanapong T, Chewatanakornkul S. Preoperative carcinoembryonic antigen and albumin in predicting survival in patients with colon and rectal carcinomas. J Clin Gastroenterol. 2006;40(7):592.CrossRefPubMed
32.
Fearon KC, Falconer JS, Slater C, Mcmillan DC, Ross JA, Preston T. Albumin synthesis rates are not decreased in hypoalbuminemic cachectic cancer patients with an ongoing acute-phase protein response. Ann Surg. 1998;227(2):249–54.CrossRefPubMedPubMedCentral
33.
Wang CY, Hsieh MJChiu YC. Higher serum C-reactive protein concentration and hypoalbuminemia are poor prognostic indicators in patients with esophageal cancer undergoing radiotherapy. Radiother Oncol. 2009;92(2):270–5.CrossRefPubMed
34.
Kormelink TG, Powe DG, Kuijpers SA, Abudukelimu A, Fens MHAM, Pieters EHE, Ven KVD, Habashy HO, Ellis IO, Blokhuis BR. Immunoglobulin free light chains are biomarkers of poor prognosis in basal-like breast cancer and are potential targets in tumor-associated inflammation. Oncotarget. 2014;5(10):3159.CrossRefPubMedCentral
35.
Steffens S, Ghazal AA, Steinestel J, Lehmann R, Wegener G, Schnoeller TJ, Cronauer MV, Jentzmik F, Schrader M, Kuczyk MA. High CRP values predict poor survival in patients with penile cancer. BMC Cancer. 2013;13(1):223.CrossRefPubMedPubMedCentral
36.
Fenner A. Kidney cancer: Postoperative CRP predicts RCC outcome after nephrectomy. Nat Rev Urol. 2010;7(11):593.CrossRefPubMed
37.
Berz D, Raymond VM, Garst JH, Erlander MG. Noninvasive urine testing of EGFR activating mutation and T790M resistance mutation in non-small cell lung cancer. Exp Hematol Oncol. 2015;5(1):24.CrossRefPubMed
38.
Ma W, Gilligan BM, Yuan J, Li T. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol. 2016;9(1):47.CrossRefPubMedPubMedCentral
Metadata
Title
Prognostic Significance of Albumin–Globulin Score in Patients with Operable Non-Small-Cell Lung Cancer
Authors
Xiang Li, MD
Sida Qin, MD
Xin Sun, MD
Dapeng Liu, MD
Boxiang Zhang, MD
Guodong Xiao, PhD
Hong Ren, MD
Publication date
01-11-2018
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 12/2018
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-6715-z

Other articles of this Issue 12/2018

Annals of Surgical Oncology 12/2018 Go to the issue

Gastrointestinal Oncology

Optimal Cutoff Values of Skeletal Muscle Index to Define Sarcopenia for Prediction of Survival in Patients with Advanced Gastric Cancer

Breast Oncology

Questions About In-Breast Tumor Recurrence in Patients Treated with Breast-Conserving Therapy

Melanoma

Treatment of Clinically Positive Cervical Lymph Nodes by Limited Local Node Excision and Adjuvant Radiotherapy in Melanoma Patients with Major Comorbidities

Thoracic Oncology

Recurrence Risk Based on Pathologic Stage After Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Implications for Risk-Based Postoperative Surveillance Strategies

Endocrine Tumors

Changes in the Evaluation and Management of Adrenocortical Carcinoma

Health Services Research and Global Oncology

An Examination of Applicants and Factors Associated with Matriculation to Complex General Surgical Oncology Fellowship Training Programs